アレルギーケア市場：世界の産業規模、シェア、動向、機会、予測、タイプ別、治療別、流通チャネル別、地域別、競合別、2019年～2029年

アレルギーケアの世界市場は2023年に218億4,000万米ドルとなり、2029年までのCAGRは7.91%で、予測期間中に目覚ましい成長を遂げると予測されています。

アレルギーケアの世界市場は、アレルギー疾患の有病率の増加、診断技術の進歩、アレルギー管理に対する意識の高まりによって大きな成長を遂げています。2023年1月に発表されたNational Center for Health Statisticsのデータによると、2021年の調査結果では、子どもの27.2％が特定のアレルギー症状に罹患していました。その内訳は、季節性アレルギーが18.9％、湿疹が10.8％、食物アレルギーが5.8％であり、米国の小児にこれらの症状が多く見られることが明らかになった。アレルギーケアには、市販薬（OTC）、処方薬、免疫療法、アレルギー検査など、アレルギーの診断、治療、管理を目的とした幅広い製品とサービスが含まれています。市場の拡大には、世界のアレルギーの発生率の上昇が寄与しており、特に呼吸器アレルギー、食物アレルギー、皮膚アレルギーが顕著です。都市化、環境汚染、ライフスタイルの変化がアレルギー負担の増大に寄与しています。特異的IgE血液検査や皮膚プリックテストなどの高度な診断ツールの利用が可能になりつつあることで、アレルギー診断の精度と効率が向上し、タイムリーで適切な治療が促進されています。

医薬品の進歩により、抗ヒスタミン薬、コルチコステロイド薬、ロイコトリエン阻害薬など、新しく効果的なアレルギー治療薬が開発され、症状の管理や患者のQOL向上のために広く使用されています。免疫療法、特に舌下療法や皮下療法は、アレルゲンに対する免疫系の反応を変化させ、潜在的な疾患修飾効果をもたらす長期的治療オプションとして支持を集めています。モバイル健康アプリケーションや遠隔医療などの技術革新は、遠隔診察、モニタリング、個別化治療計画の提供によってアレルギーケアを変革しつつあります。

主要市場促進要因

呼吸器アレルギーの増加

新薬の開発

主な市場課題

ヘルスケアサービスへのアクセス制限

アレルギー治療の高コスト

主要市場動向

食物アレルギーの発生率の増加

食物アレルギーの発生率の増加は、世界市場の重要な促進要因であり、世界中の数百万人に影響を及ぼしています。

診断技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界のアレルギーケア市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（目のアレルギー、鼻炎、喘息、皮膚アレルギー、食物アレルギー、その他のアレルギー）
  • 治療別（抗アレルギー薬、免疫療法）
  • 流通チャネル別（病院、オンライン薬局、小売薬局、その他）
  • 企業別（2023）
  • 地域別
• 市場マップ

第6章 北米のアレルギーケア市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 治療別
  • 流通チャネル別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のアレルギーケア市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 治療別
  • 流通チャネル別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のアレルギーケア市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 治療別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のアレルギーケア市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 治療別
  • 流通チャネル別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのアレルギーケア市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 治療別
  • 流通チャネル別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併および買収（該当する場合）
• 製品の発売（ある場合）
• 最近の動向

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• ALK-Abello A/S
• AbbVie Inc.
• Allergy Therapeutics PLC
• Bausch Health Companies Inc.
• Alembic Pharmaceuticals Limited
• F. Hoffmann-La Roche Ltd
• Nicox SA
• GlaxoSmithKline PLC
• Johnson & Johnson
• LETI Pharma, S.L.U

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Allergy Care Market was valued at USD 21.84 Billion in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.91% through 2029. The Global Allergy Care Market is experiencing significant growth driven by the increasing prevalence of allergic conditions, advancements in diagnostic technologies, and heightened awareness of allergy management. According to the National Center for Health Statistics data published in January 2023, findings from 2021 indicated that 27.2% of children were affected by selected allergic conditions. This included 18.9% experiencing seasonal allergies, 10.8% with eczema, and 5.8% dealing with food allergies, highlighting the significant prevalence of these conditions among children in the United States. Allergy care encompasses a wide range of products and services designed to diagnose, treat, and manage allergies, including over the counter (OTC) medications, prescription drugs, immunotherapy, and allergy testing. The market's expansion is fueled by the rising incidence of allergies worldwide, particularly respiratory allergies, food allergies, and skin allergies. Urbanization, environmental pollution, and changing lifestyles contribute to the growing allergy burden. The increasing availability of advanced diagnostic tools, such as specific IgE blood tests and skin prick tests, has enhanced the accuracy and efficiency of allergy diagnosis, facilitating timely and appropriate treatment.

Pharmaceutical advancements have led to the development of new and effective allergy medications, including antihistamines, corticosteroids, and leukotriene inhibitors, which are widely used to manage symptoms and improve patients' quality of life. Immunotherapy, particularly sublingual and subcutaneous methods, is gaining traction as a long-term treatment option that modifies the immune system's response to allergens, offering potential disease-modifying effects. Technological innovations such as mobile health applications and telemedicine are transforming allergy care by providing remote consultation, monitoring, and personalized treatment plans.

Key Market Drivers

Rise in Respiratory Allergies

One of the primary drivers of the Global Allergy Care Market is the rising prevalence of respiratory allergies. Conditions such as allergic rhinitis, asthma, and chronic obstructive pulmonary disease (COPD) are becoming increasingly common due to various environmental and lifestyle factors. Urbanization plays a significant role, as it brings about increased exposure to pollution and allergens. Rapid industrialization and vehicular emissions contribute to higher levels of airborne pollutants, including particulate matter, nitrogen dioxide, and sulfur dioxide, which can aggravate respiratory conditions.

Pollution is a major contributing factor, with studies showing a direct correlation between pollution levels and the incidence of respiratory allergies. Pollutants can irritate the respiratory tract, leading to inflammation and increased sensitivity to allergens. In urban areas, the concentration of allergens such as pollen, dust mites, and pet dander is higher, further exacerbating the problem. These allergens can trigger allergic reactions, resulting in symptoms like sneezing, coughing, wheezing, and shortness of breath.

Changing climatic conditions also influence the prevalence of respiratory allergies. Global warming and climate change are altering pollen seasons, increasing the amount and distribution of airborne pollen. Longer and more intense pollen seasons mean that individuals are exposed to allergens for extended periods, heightening the risk of developing allergic reactions. Extreme weather events, such as storms and wildfires, can release large amounts of allergens and pollutants into the air, further contributing to respiratory issues.

The increase in airborne pollutants and allergens has led to a higher demand for allergy diagnostics and treatments. Healthcare providers are increasingly relying on advanced diagnostic tools to accurately identify specific allergens and tailor treatment plans. The development of new medications, such as advanced antihistamines, corticosteroids, and leukotriene inhibitors, offers improved symptom management. Immunotherapy is gaining traction as a long-term solution for modifying the immune response to allergens, providing sustained relief from respiratory allergies. As a result, the rising prevalence of respiratory allergies continues to drive growth in the Global Allergy Care Market.

Development of New Medications

Pharmaceutical advancements have significantly transformed the management of allergies, leading to the development of new and more effective medications. These innovations offer better symptom control and fewer side effects, substantially enhancing the quality of life for individuals suffering from allergies. The evolution of modern antihistamines, corticosteroids, and leukotriene inhibitors represents a major leap forward in allergy treatment. Modern antihistamines, such as cetirizine, loratadine, and fexofenadine, have been designed to target histamine receptors more selectively. These medications effectively reduce symptoms like itching, sneezing, and runny nose without causing the sedation commonly associated with first-generation antihistamines. Their improved safety profile and longer-lasting effects make them a preferred choice for many patients, driving demand in the allergy care market.

Corticosteroids, available in various forms such as nasal sprays, inhalers, and oral tablets, are another cornerstone of allergy management. These medications work by reducing inflammation and suppressing the immune response that triggers allergic reactions. Modern corticosteroids, like fluticasone and mometasone, offer potent anti-inflammatory effects with minimal systemic absorption, reducing the risk of side effects. This makes them highly effective for managing conditions such as allergic rhinitis and asthma, providing long-term relief and improving patients' daily functioning.

Leukotriene inhibitors, such as montelukast, represent another class of medications that have gained prominence in allergy management. These drugs block leukotrienes, inflammatory chemicals released during an allergic reaction, thus preventing airway constriction and inflammation. They are particularly beneficial for individuals with asthma and allergic rhinitis, offering an additional option for those who do not respond well to antihistamines or corticosteroids.

The continuous development of these advanced medications has not only improved symptom management but also expanded the treatment options available to healthcare providers. This diversification allows for more personalized and effective treatment plans tailored to the specific needs of each patient. Consequently, the demand for pharmaceutical products in the allergy care market has seen a significant boost.

Key Market Challenges

Limited Access to Healthcare Services

One of the major challenges hindering the Global Allergy Care Market is the limited access to healthcare services, especially in low- and middle-income countries. Many regions lack adequate healthcare infrastructure, including specialized clinics and trained professionals to diagnose and treat allergies. This lack of resources prevents a significant portion of the global population from accessing necessary allergy care, leading to underdiagnosis and undertreatment. In rural and remote areas, healthcare facilities are often scarce, and residents must travel long distances to reach medical centers. This inconvenience discourages people from seeking timely medical attention for allergic conditions. There is often a shortage of allergists and trained healthcare providers who can offer specialized care. General practitioners may lack the expertise to properly diagnose and manage complex allergy cases, resulting in misdiagnosis or suboptimal treatment.

Efforts to improve access to healthcare services include investing in healthcare infrastructure, training more specialists, and implementing telemedicine solutions. However, these initiatives require substantial financial investment and time, posing a significant barrier to immediate improvements. Addressing this challenge is crucial for expanding the reach of allergy care and ensuring that individuals worldwide receive appropriate diagnosis and treatment.

High Cost of Allergy Treatments

The high cost of allergy treatments is another significant barrier in the Global Allergy Care Market. Many advanced diagnostic tools and effective treatments, such as immunotherapy, are expensive and often not covered by health insurance, making them inaccessible to a large segment of the population. The cost of allergy medications, including antihistamines, corticosteroids, and epinephrine auto-injectors, can also be prohibitively high for many patients. Pharmaceutical companies invest heavily in research and development to bring new and improved allergy treatments to market. These costs are often passed on to consumers, resulting in high prices for the latest medications and therapies. For patients requiring long-term treatment, these expenses can accumulate, leading to financial strain and reduced adherence to prescribed regimens. The lack of affordable options can force patients to rely on less effective over-the-counter medications, which may not provide adequate relief.

Insurance coverage for allergy treatments varies widely across different regions and healthcare systems. In many countries, essential allergy treatments are not included in standard health insurance plans, leaving patients to bear the full cost. Efforts to reduce the cost of allergy care include advocating for better insurance coverage, promoting the use of generic medications, and implementing policies to regulate drug prices. Overcoming this challenge is essential to making allergy care more accessible and affordable for all individuals.

Key Market Trends

Growing Incidence of Food Allergies

The growing incidence of food allergies is a significant driver of the Global Allergy Care Market, affecting millions of individuals across the globe.

According to the National Center for Health Statistics, as of 2021, approximately 20 million individuals in the United States are affected by food allergies. This includes around 16 million adults (6.2% of the adult population) and approximately 4 million children (5.8% of the child population) grappling with this health condition. Common food allergens such as peanuts, tree nuts, milk, eggs, soy, wheat, fish, and shellfish are increasingly causing severe allergic reactions. These reactions can range from mild symptoms like itching and hives to life-threatening anaphylaxis, characterized by difficulty breathing, swelling, and a drop in blood pressure. This alarming rise in food allergies has prompted a greater need for accurate diagnostic tools and effective management strategies.

The heightened awareness of food allergies has led to increased demand for precise diagnostic methods. Traditional tests like skin prick tests and specific IgE blood tests are commonly used to identify food allergens. However, advancements in diagnostic technologies have introduced more refined techniques, such as component-resolved diagnostics (CRD), which can pinpoint specific proteins within allergens responsible for triggering reactions. This level of precision aids in creating more targeted and personalized treatment plans for individuals with food allergies.

Effective management strategies are crucial for those living with food allergies. The market for allergen-free foods has expanded significantly, offering a wider variety of safe alternatives for consumers. These products are carefully manufactured to avoid cross-contamination and provide safe options for those with dietary restrictions. The development and widespread availability of epinephrine auto-injectors, such as EpiPens, have become essential for managing severe allergic reactions. These devices deliver a life-saving dose of epinephrine in emergencies, preventing anaphylaxis and buying critical time for medical intervention.

Public health campaigns and educational programs have also played a vital role in raising awareness about food allergies. These initiatives educate the public about the importance of reading food labels, recognizing symptoms of allergic reactions, and understanding the proper use of epinephrine auto-injectors. As a result, more individuals are seeking diagnosis and treatment, leading to increased demand for allergy care products and services.

Advancements in Diagnostic Technologies

Technological advancements in diagnostic tools have significantly improved the accuracy and efficiency of allergy diagnosis. Traditional methods, such as skin prick tests and patch tests, have been complemented and sometimes replaced by more advanced techniques, enhancing diagnostic precision. Specific IgE blood tests, for instance, measure the levels of immunoglobulin E antibodies to particular allergens in the blood, providing a clear indication of sensitization to specific substances. This method offers a reliable alternative for patients who cannot undergo skin tests due to skin conditions or other contraindications.

Component-resolved diagnostics (CRD) represent another significant leap forward. CRD allows for the identification of specific allergenic proteins within a particular allergen. This granular level of detail helps healthcare providers distinguish between primary sensitization and cross-reactivity, thereby refining the diagnosis and informing more targeted treatment strategies. These advancements not only improve the diagnostic process but also facilitate the development of personalized treatment plans, enhancing patient outcomes and driving demand for allergy care products.

The integration of digital health technologies is revolutionizing the allergy care landscape. Mobile health applications and telemedicine platforms are making healthcare more accessible and convenient for patients with allergic conditions. These technologies allow for remote consultation, enabling patients to connect with healthcare providers without the need for in-person visits. This is particularly beneficial for individuals in remote or underserved areas, where access to specialized allergy care may be limited.

Digital health platforms also enable continuous monitoring and management of allergic conditions. Patients can use mobile apps to track their symptoms, medication usage, and exposure to potential allergens. This real-time data collection allows healthcare providers to monitor patient progress more closely and adjust treatment plans as needed. Telemedicine consultations can provide immediate guidance and support, helping patients manage acute allergic reactions effectively.

Digital platforms can deliver personalized treatment plans based on the collected data, enhancing patient adherence and engagement. For example, apps can send reminders for medication, suggest avoidance strategies based on local pollen forecasts, and provide educational resources about managing allergies. These features empower patients to take an active role in their allergy management, leading to better health outcomes.

Segmental Insights

Type Insights

Based on the Type, In 2023, the rhinitis segment emerged as the dominant segment in the Global Allergy Care Market. This prominence is largely attributed to the widespread prevalence of allergic rhinitis, commonly known as hay fever, which affects a significant portion of the global population. Allergic rhinitis is triggered by environmental allergens such as pollen, dust mites, mold, and pet dander, making it a pervasive condition in both urban and rural areas. Several factors contribute to the dominance of the rhinitis segment including increasing pollution levels and urbanization have led to higher exposure to allergens, exacerbating the incidence of allergic rhinitis. Urban environments, with their higher concentrations of pollutants and irritants, contribute significantly to the rising cases of this condition.

The availability of a wide range of treatment options for allergic rhinitis, including antihistamines, corticosteroids, and immunotherapy, has made it easier for patients to manage their symptoms effectively. The development of non-sedating antihistamines and intranasal corticosteroids has improved patient compliance and outcomes, further driving the market growth.

Treatment Insights

Based on the treatment segment, in 2023, the anti-allergy drugs segment emerged as the dominant segment in the Global Allergy Care Market. Anti-allergy drugs such as antihistamines, corticosteroids, and leukotriene inhibitors continue to be the primary treatment options for managing allergic conditions. These medications effectively alleviate symptoms such as sneezing, itching, nasal congestion, and hives, providing immediate relief to patients experiencing allergic reactions.

The availability of a wide range of anti-allergy drugs catering to different allergic conditions contributes to the segment's dominance. For instance, non-sedating antihistamines like cetirizine and loratadine are preferred for their minimal side effects and efficacy in treating allergic rhinitis and urticaria. Nasal corticosteroid sprays such as fluticasone and mometasone are highly effective in reducing nasal inflammation and congestion associated with allergic rhinitis. These diverse treatment options allow healthcare providers to tailor therapy according to the specific needs and symptoms of each patient.

Advancements in pharmaceutical research and development have led to the introduction of newer and more effective anti-allergy drugs with improved safety profiles. The continuous innovation in drug formulations and delivery systems, such as extended-release tablets and nasal sprays, enhances patient compliance and treatment outcomes.

Regional Insights

North America emerged as the dominant region in the Global Allergy Care Market in 2023, holding the largest market share due to several key factors. The region experiences a high prevalence of allergic conditions, including allergic rhinitis, asthma, and food allergies, among its population. Environmental factors such as pollen, air pollution, and indoor allergens contribute significantly to the incidence and severity of allergies, driving demand for allergy diagnostics and treatments North America benefits from advanced healthcare infrastructure and extensive research and development activities in the field of allergy care. The region is home to leading pharmaceutical companies, research institutions, and healthcare providers specializing in allergy treatments. This ecosystem fosters innovation in allergy diagnostics, medications, and immunotherapy, offering patients access to cutting-edge treatments and personalized care options.

There is a strong emphasis on public health awareness and education regarding allergies in North America. Government initiatives, healthcare campaigns, and educational programs raise awareness about allergy prevention, symptoms recognition, and treatment options among the general population and healthcare professionals. This proactive approach encourages early diagnosis and management of allergies, contributing to the overall market growth.

Key Market Players

ALK-Abello A/S

AbbVie Inc.

Allergy Therapeutics PLC

Bausch Health Companies Inc.

Alembic Pharmaceuticals Limited

F. Hoffmann-La Roche Ltd

Nicox SA

GlaxoSmithKline PLC

Johnson & Johnson

LETI Pharma, S.L.U

Report Scope:

In this report, the Global Allergy Care Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Allergy Care Market, By Type:

Eye Allergy Rhinitis Asthma Skin Allergy Food Allergies Other Allergies

Allergy Care Market, By Treatment:

Anti-Allergy Drugs Immunotherapy

Allergy Care Market, By Distribution Channel:

Hospital Online Pharmacies Retail Pharmacies Others

Allergy Care Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Allergy Care Market.

Available Customizations:

Global Allergy Care market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Allergy Care Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Eye Allergy, Rhinitis, Asthma, Skin Allergy, Food Allergies, Other Allergies)
  • 5.2.2. By Treatment (Anti-Allergy Drugs, Immunotherapy)
  • 5.2.3. By Distribution Channel (Hospital, Online Pharmacies, Retail Pharmacies, Others)
  • 5.2.4. By Company (2023)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Allergy Care Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Allergy Care Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Mexico Allergy Care Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Canada Allergy Care Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment
      • 6.3.3.2.3. By Distribution Channel

7. Europe Allergy Care Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Allergy Care Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Allergy Care Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Allergy Care Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Allergy Care Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Allergy Care Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Allergy Care Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Allergy Care Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Allergy Care Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. South Korea Allergy Care Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Japan Allergy Care Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Allergy Care Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment
      • 8.3.5.2.3. By Distribution Channel

9. South America Allergy Care Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Allergy Care Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Allergy Care Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Allergy Care Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Allergy Care Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Allergy Care Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Allergy Care Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Allergy Care Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porters Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. ALK-Abello A/S
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. AbbVie Inc.
• 14.3. Allergy Therapeutics PLC
• 14.4. Bausch Health Companies Inc.
• 14.5. Alembic Pharmaceuticals Limited
• 14.6. F. Hoffmann-La Roche Ltd
• 14.7. Nicox SA
• 14.8. GlaxoSmithKline PLC
• 14.9. Johnson & Johnson
• 14.10. LETI Pharma, S.L.U

15. Strategic Recommendations

16. About Us & Disclaimer